 |
|
HPV Vaccines—Prophylactic, Not Therapeutic
Lauri E. Markowitz, MD
JAMA. 2007;298:805-806.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Two human papillomavirus (HPV) L1 viruslike particle (VLP) vaccines have been developed against HPV types 16 and 18—the 2 HPV types that account for about 70% of cervical cancers worldwide.1 Both vaccines have been found to have high prophylactic efficacy in large clinical trials.2-6
In this issue of JAMA, Hildesheim and colleagues7 report the effect of vaccination with one of these vaccines, the bivalent HPV-16/18 vaccine, on viral clearance. These results are from an ongoing community-based trial of more than 7000 18- to 25-year-old women in Costa Rica. The main analysis of the ongoing trial, as for other recently published trials of HPV vaccines,2-5 will focus on vaccine efficacy among women not infected with the specific HPV vaccine types at the time of enrollment. In contrast, the analysis by Hildesheim et al addresses the question of whether the vaccine can clear HPV type 16/18 infection . . . [Full Text of this Article]
Author Affiliation: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
RELATED ARTICLE
Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial
Allan Hildesheim, Rolando Herrero, Sholom Wacholder, Ana C. Rodriguez, Diane Solomon, M. Concepcion Bratti, John T. Schiller, Paula Gonzalez, Gary Dubin, Carolina Porras, Silvia E. Jimenez, Douglas R. Lowy, and for the Costa Rican HPV Vaccine Trial Group
JAMA. 2007;298(7):743-753.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
New, and Some Not-so-New, Vaccines for Adolescents and Diseases They Prevent
Fishbein et al.
Pediatrics 2008;121:S5-S14.
ABSTRACT
| FULL TEXT
|
